ALFA Filings
Every announcement, straight from the exchange
Every Novartis India other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements
Novartis India Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations. This is a routine periodic disclosure.
Novartis India Limited has changed its corporate name to Evonile Pharma Limited, effective October 01, 2026, following approval from the Ministry of Corporate Affairs.
Novartis India dispatched physical letters with the FY25-26 Annual Report web-link to non-email shareholders per Reg 36(1)(b). This is a routine compliance communication with no financial or business impact.
This is the quarterly shareholding pattern filing for Novartis India Ltd as per SEBI regulations. No significant corporate event is disclosed in this submission.
Novartis India Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details the distribution of shares across promoter and public categories.
Novartis India Limited filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory adherence with no significant non-compliances noted.